ALZN - CIK 0001677077
The table below shows Alzamend Neuro, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.36M | -$1.06M | -$3.30M | -$2.54M | -$1.22M | -$205.10K |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | -$90.00K | -$147.24K | - | - | $100.92K |
| Dividends paid | - | - | - | - | - |
Alzamend Neuro, Inc. reported operating cash flow of -$6.57M for fiscal year 2025. That is up 20.6% from -$8.27M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$2.35M (FY 2020) to -$6.57M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $4.04M | $1.96M | - | - | $14.91M | $77.01K |